December 23, 2009 โ The Cleveland Clinic this week initiated a phase II trial examining a new oral therapy for the treatment of atherosclerosis in patients with stable coronary artery disease (CAD).
December 22, 2009 โ A new study is the first to specifically identify the year immediately around a womanโs final menstrual period as the time of most adverse changes in the lipid profile in women. The study appears in the Dec. 15-22, 2009, print double issue of the Journal of the American College of Cardiology (JACC) and the Prevention and Outcomes Quarterly Focus Issue.
December 22, 2009 โ A drug manufacturer recently filed paperwork with the FDA to produce a generic version of the cholesterol-lowering medication Vytorin.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
December 21, 2009 โ Revised guidelines on the use of beta-blockers for noncardiac surgery say therapy should neither be initiated on the day of surgery, nor stopped abruptly peri- or postoperatively.
December 21, 2009 โ The recently introduced GORE PROPATEN Vascular Graft has integrated rings that reduce the cross-sectional profile by 24 percent as compared to externally ringed grafts, and its radial reinforcement allows for improved blood flow.
December 18, 2009 โ Results from the Europella registry, evaluating the safety and feasibility of the Abiomed Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention (PCI) procedures, was published in the Dec. 15 issue of the Journal of the American College of Cardiology (JACC).
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
December 18, 2009 - The U.S. radiopharmacy network currently owned by Covidien is being sold to Triad Isotopes in a deal announced today. Covidien said it decided to divest its network of 37 Mallinckrodt radiopharmacies after evaluating the radiotracer market. The company said it wants to streamline its portfolio and concentrate resources in its faster-growing, higher-margin businesses.
December 19, 2009 โ A new, non-electronic computed tomography (CT) radiation dosimeter was released this week. The RADView CT dosimeter is manufactured in the form of a badge, smaller than a credit card, and contains radiation-sensitive film.
December 17, 2009 โ The American College of Cardiology (ACC) recently certified LUMEDX, a provider of integrated cardiovascular imaging and information systems, as an ACC-NCDR ACTION Registry-GWTG software vendor.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 17, 2009 โ The University of Virginia (UVa) in Charlottesville and AstraZeneca this week entered into a strategic research collaboration to enhance development of new treatments, primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).
December 16, 2009 - Many healthcare providers who are pursuing meaningful use objectives and meeting with deadlines defined within the HITECH provision of the American Recovery and Reinvestment Act (ARRA) are challenged with securing the capital investment needed to meet the aggressive schedules.
December 16, 2009 - Non-enhanced CT for calcium detection is a reliable way to exclude obstructive coronary artery disease in patients with chest pain, according to a study published in the December issue of the American Journal of Cardiology.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
December 16, 2009 โ The FDA's Endocrinologic and Metabolic Drugs Advisory Committee yesterday agreed AstraZeneca established sufficient benefit with trial data showing prophylactic benefit of prescribing CRESTOR (rosuvastatin calcium) to healthy individuals to prevent heart disease.
December 16, 2009 โ Patient enrollment was recently completed for a study evaluating the ability of cardiopoietic cells to restore cardiac function in heart failure patients.
December 15, 2009 โ The Department of Defense (DoD) awarded a contract to Philips Healthcare for its HeartStart MRx monitor/defibrillator, which has the potential of generating more than $29 million for the company.